Najy Alsayed | Global Therapeutic Area Head - Infectious Diseases Menarini Group
Menarini Group

Najy Alsayed, Global Therapeutic Area Head - Infectious Diseases Menarini Group, Menarini Group

Currently, Global Therapeutic Area Head for Infectious Diseases at Menarini Group. His over 25 years’ experience and expertise in Pharma covers various disease fields including CNS, Gastroenterology, Bone diseases, oncology and infectious disease & vaccines at Pfizer, Procter & Gamble Pharma, Novartis, Sanofi-Pasteur-MSD, CUBIST, MSD and Menarini Group. Prior to joining Pharma, he practiced for several years as clinician in internal medicine & nephrology and as a researcher in CV and lipid metabolism in Paris, France and at the NIH in Bethesda, USA. He is a lecturing professor at EUDIPHARM University of Lyon-France, a keynote speaker and a primary author of a number of international publications. He is also a member of the European Society for Pediatric Infectious Diseases (ESPID), The European Society of Intensive Care Medicine (ESICM), The Infectious Diseases Society of America (IDSA) and a Board member in 2 Biotech companies and at AMR industry alliance After graduating from Medical School he did his internship training in Paris and undertook a master degree in clinical biochemistry at the university René Descartes-Paris V followed by a degree in international sales and marketing at IFIP in Paris, France.

Appearances:



Day 1 - World Antimicrobial Resistance Congress & Disease Prevention Control Summit 2024 @ 16:30

Keynote panel: From awareness to action: Identifying tailored solutions for AMR

The need for a coordinated cross-sector response to the AMR crisis is abundantly clear. Yet mobilizing a wide-ranging network of stakeholders in a challenged and resource-constrained environment is no small task. This panel draws upon insights from advocacy and industry to identify opportunities and illuminate a pathway to meaningful solutions.

Sponsored by Menarini Group

last published: 14/Nov/24 16:45 GMT
last published: 14/Nov/24 16:45 GMT

back to speakers